TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $32,534,016 | -17.1% | 2,118,100 | +21.4% | 0.59% | -23.4% |
| Q1 2023 | $39,229,307 | +48.9% | 1,744,300 | +39.2% | 0.77% | +52.8% |
| Q4 2022 | $26,353,324 | -14.7% | 1,253,130 | 0.0% | 0.50% | -12.0% |
| Q3 2022 | $30,877,000 | +65.0% | 1,253,130 | +62.3% | 0.57% | +69.0% |
| Q2 2022 | $18,710,000 | +41.9% | 772,200 | +46.2% | 0.34% | +175.6% |
| Q1 2021 | $13,187,000 | – | 528,100 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |